• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Day 2 Recap: 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference


Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

To stay informed on conference insights, subscribe to receive our eNewslettters.

Safety vs Efficacy: What AD Treatments Can Be Used in Pediatric Patients?

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Comparing AD Guidelines From Around the World

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Exploring New Pathways in Atopic Dermatitis

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Looking Ahead to Advancements in Vitiligo and Atopic Dermatitis

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Addressing Itch and Remission in Atopic Dermatitis

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

Late-Breaker: Roflumilast Cream 0.15% Demonstrates Continued Improvement in AD Symptoms Through 56 Weeks

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Late-Breaker: Upadacitinib Demonstrates Superiority Over Dupilumab in All Ranked Secondary End Points of Head-to-Head AD Study

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Prioritizing Itch and Sleep Improvement in Atopic Dermatitis

Prioritizing Itch and Sleep Improvement in Atopic Dermatitis

Battle of the Two Titans: When to Progress AD Patients to Systemic Therapy

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC debated what patients are a contender for systemic therapy.

To view all conference coverage from RAVE, click here.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.